Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

US FDA Scientists Give Leadership High Marks, But Some Worry About Industry Influence

Aug 21 2018

• By Brenda Sandburg

Related Content

Woodcock's 'Bias' In Sarepta Case Made Jenkins Worry About Future Drug Reviews

Aug 01 2017

FDA Pushes For Scientific Integrity As Staff Criticize Corporate Influence In External Survey

Mar 12 2012

US FDA Hiring For Senior Staff Vacancies Boosted By Cures Act, Pilot Program – Gottlieb

May 08 2018

FDA's Hiring Advantage: Scores In Best Places To Work Survey Continue To Rise

Feb 07 2018

US FDA Taps Pfizer Executive For CDER Deputy Director Slot

Feb 02 2018

FDA Scientists Fear Retaliation For Conveying Health Risks, Survey Finds

Jul 24 2006

Molecular Dx Exec Named New US FDA Diagnostics Chief

Aug 09 2018

Sequester Travel: Halved FDA Budget Limits Opportunities For Scientists, Impacts Senior Officials Too

Sep 16 2013

Merck R&D Exec Jumps To US FDA As Office Of New Drugs Deputy Director

Nov 09 2016

Related Companies

Sarepta Therapeutics, Inc.

Sanofi

Merck & Co., Inc.

Johnson & Johnson

Sanofi Genzyme

Pfizer Inc.

Merck & Co., Inc.

Additional Topics

United States FDA Regulation Medical Device

More from Regulation

More from Policy & Regulation

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window